The challenging estrogen receptor-negative/progesterone receptor-negative/HER-2-negative patient: A promising candidate for epidermal growth factor receptor-targeted therapy?

Breast Journal

Volumn 12, Issue 4, 2006, Pages 360-362

  Siziopikou, Kalliopi P ^a   Ariga, Reshma ^a   Proussaloglou, Kimon E ^a   Gattuso, Paolo ^a   Cobleigh, Melody ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Breast cancer; EGFR; HER 2; Targeted therapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GRADING; DRUG MECHANISM; DRUG TARGETING; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC HETEROGENEITY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; PATIENT SELECTION; SIGNAL TRANSDUCTION; TREATMENT PLANNING;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; ENZYME INHIBITORS; FEMALE; HUMANS; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 33745590399     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/j.1075-122X.2006.00276.x     Document Type: Article

References (23)

1. Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005;23:2445-59.
2. Spector NL, Xia W, Burris H, et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 2005;23:2502-12.
3. Laskin JJ, Sandler AB. Epidermal growth factor receptor: a promising target in solid tumours. Cancer Treat Rev 2004;30:1-17.
4. Tedesco KL, Lockhart AC, Berlin JD. The epidermal growth factor receptor as a target for gastrointestinal cancer therapy. Curr Treat Options Oncol 2004;5:393-403.
5. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005;353:172-87.
6. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
7. Herceptin combined with chemotherapy improves disease-free survival for patients with early breast cancer. Bethesda. MD: National. Cancer Institute, April 25, 2005 (at http://www.nci.nih.gov/newscenter/pressreleases/).
8. Averbuch S, Kcenler M, Morris C, Wakeling A. Therapeutic potential of tyrosine kinase inhibitors in breast cancer. Cancer Invest 2003;21:782-91.
9. Green MR. Targeting targeted therapy. N Engl J Med 2004;350:2191-93.
10. Mass RD. The HER receptor family: a rich target for therapeutic development. Int J Radiat Oncol Biol Phys 2004;58:932-40.
11. Pao W, Miller VA. Epidermal growth factor receptor mutations, small molecule kinase inhibitors and non-small cell lung cancer: current knowledge and future directions. J Clin Oncol 2005;23:2556-68.
12. Herbst RS, Bunn PA. Targeting the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res 2003;9:5813-24.
13. Huang S, Liu H, Li L, et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 2004;10:8195-203.
14. Atalay G, Gardoso F, Awada A, Piccart MJ. Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer. Ann Oncol 2003;14:1346-63.
15. Tan AR, Yang X, Hewitt SM, et al. Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J Clin Oncol 2004;22:3080-90.
16. Guix M, Kelley MC, Reyzer ML, et al. Short course of EGFR tyrosine kinase inhibitor erlotinib (OSI-774, Tarceva) reduces tumor cell proliferation and active MARK in situ in untreated operable breast cancers: a strategy for patient selection into phase II trials with signaling inhibitors. Breast Cancer Res Treat 2004;88(suppl):S34.
17. Sartor CI, Zhou H, Perou CM, Ethier SP. Basal-like breast tumor-derived cell lines are growth inhibited and radiosensitized by epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. Breast Cancer Res Treat 2004;88(suppl):S34.
18. Lu C, Speers C, Zhang Y, et al. Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. J Natl Cancer Inst 2003;95:1825-33.
19. Cunliffe HE, Ringner M, Bilke S, et al. The gene expression response of breast cancer to growth regulators: patterns and correlation with tumor expression profiles. Cancer Res 2003;63:7158-66.
20. Rouzier R, Perou C, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005;11:5678-85.
21. Perou CM, Sorlie T, van Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
22. van't Veer LJ, Dai H, van de Vijver MJ. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-36.
23. Sorlie T, Perou CM, Tibshinari R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-74.